EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Xlife Sciences AG (XLS) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Xlife Sciences AG CHF 9.07, price CHF 12.30, upside -26.3%, quality 24 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CH · ISIN CH0461929603

XS Thin data Sep 23, 2026

Xlife Sciences AG

XLS · SW

Weak valuationQuality is weak on top of the rich price.

!Fair value CHF 9.07 · Overvalued (−26%)
!Quality 24/100
!Weak Growth (revenue 5y −7.1 %/yr)
!Low debt · negative free cash flow
✓Ranks above peers (5/7)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
!The models disagree: range CHF 4.82 to CHF 16.21
!Weak on future: 7 out of 100
Watch Xlife Sciences AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 52.00 CHF 12.30 Fair Value CHF 9.07 Feb 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

55‑month range CHF 12.30 – CHF 52.00 · fair‑value band CHF 4.82 – CHF 16.21 · the CHF 12.30 price screens above the CHF 9.07 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Xlife Sciences in your weekly email

Every Wednesday you see whether Xlife Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector.

Show more

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services. In addition, the company builds a bridge between research/ development and healthcare markets, as well as support researchers and entrepreneurs in the positioning, structuring, development, and implementation of their ideas; and operates as an active ingredient manufacturer. Further, it focuses on identifying innovative biomarkers in the field of kidney diseases; the development of antibody-drug conjugates through a click chemistry approach and microfluidic screening of functional antibodies; and provides Neuromex, a screening instrument for the early-stage detection of neurological diseases. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.

Stock analysis

Xlife Sciences AG (XLS) currently trades at CHF 12.30, while our model-based Fair Value estimate is CHF 9.07, implying the stock looks roughly 35.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: CHF 4.82 (bear) to CHF 16.21 (bull), the price of CHF 12.30 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Xlife Sciences AG reported revenue of CHF 275K in FY2025 versus CHF 806K in FY2021, a compound −23.6%/yr. Reported net income was −CHF 21.5M in FY2025.

Key figures

Market cap CHF 102M · EPS (TTM) CHF −3.76 · Return on equity −7.1% · Return on assets (EBIT) −3.8% · Operating margin 28,004% · Revenue (TTM) CHF 275K · Revenue growth (YoY) +1.3% · EPS growth (YoY) +94.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −26%, XLS screens richer than that median.

Fair Value models

Bear CHF 4.82 Fair Value CHF 9.07 Bull CHF 16.21
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings n/a CHF 1.15 CHF 4.57 73
NCAV (Graham) CHF 24.84 CHF 33.29 CHF 49.68 54
All 2 models by family
DCF Models
Owner Earnings n/a CHF 1.15 CHF 4.57 73
Asset-Based
NCAV (Graham) CHF 24.84 CHF 33.29 CHF 49.68 54

Open the full fair value analysis →

Notify me when XLS reaches fair value

Put XLS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 24/100

Of which business quality 25 · Market factors (momentum, volatility) 17

Profitability 1
Margins and returns on capital today
Quality Growth 12
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 43
Balance sheet, leverage, solvency risk
Investment 52
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 5
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 64
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−67.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−779.5% (2020) → −11,462.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

XLS screens 36% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Xlife Sciences AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −26% · Above median
Profitability
Return on assets −4% · Above median
Growth and dividend
Revenue growth 1% · Above median
Balance sheet
Debt / equity 0.19× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.43× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)7 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)91 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Xlife Sciences AG · Fair Value
CHF 9.07 −36%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Xlife Sciences AG Fair Value". https://www.fairvalue-calculator.com/stock/XLS

Frequently asked questions

Is Xlife Sciences AG (XLS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of CHF 9.07 versus a price of CHF 12.30, about −26% upside (overvalued).
What is the fair value of XLS?
Our model-based fair value for Xlife Sciences AG is CHF 9.07 (as of Sep 23, 2026), built from audited fundamentals. The current price: CHF 12.30.
What is the quality score of XLS?
Xlife Sciences AG has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xlife Sciences AG (XLS)?
Our model-based price target is the fair value of CHF 9.07 (as of Sep 23, 2026) from 2 valuation models. Cautious scenario CHF 4.82, optimistic scenario CHF 16.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Xlife Sciences AG stock forecast for 2026?
Our models put fair value at CHF 9.07, about −26% upside versus a price of CHF 12.30 (overvalued). Cautious scenario CHF 4.82, optimistic scenario CHF 16.21. The calculation is refreshed regularly with new filings.
What is the revenue of Xlife Sciences AG (XLS)?
Xlife Sciences AG reported trailing-twelve-month revenue of about CHF 275K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Xlife Sciences AG (XLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xlife Sciences AG it is CHF 9.07 per share (as of Sep 23, 2026), against a price of CHF 12.30. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Xlife Sciences AG stock overvalued or undervalued in 2026?
As of Sep 23, 2026, XLS trades above its calculated fair value: price CHF 12.30, fair value CHF 9.07, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XLS?
No. The price is what the market pays today (CHF 12.30); the fair value is what the company's own numbers justify (CHF 9.07). For Xlife Sciences AG the two are CHF 3.23 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xlife Sciences AG worth?
The market values Xlife Sciences AG at about CHF 102M (market capitalisation, as of Sep 23, 2026). Per share that is CHF 12.30; our models calculate a fair value of CHF 9.07 per share.
What do the bullish and bearish scenarios say about XLS?
Our models span a range for Xlife Sciences AG: cautious scenario CHF 4.82, base CHF 9.07, optimistic CHF 16.21 per share (as of Sep 23, 2026, price CHF 12.30). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Xlife Sciences AG (XLS)?
Balance-sheet figures for Xlife Sciences AG (as of Sep 23, 2026): return on equity −7.1%, debt of 0.19 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is XLS from its 52-week high?
Xlife Sciences AG trades at CHF 12.30, about 53% below its 52-week high of CHF 26.00 and at the low of CHF 12.30 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 9.07 is for.
Which stocks are comparable to Xlife Sciences AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xlife Sciences AG stock attractive at the current price?
The data as of Sep 23, 2026: price CHF 12.30, calculated fair value CHF 9.07 (−26%), Quality Score 24/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XLS calculated?
We run Xlife Sciences AG through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 9.07, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Xlife Sciences AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xlife Sciences AG (XLS)?
The closing price on Sep 23, 2026 was CHF 12.30. Our model-based fair value is CHF 9.07, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xlife Sciences AG right now?
Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (CHF 4.82 to CHF 16.21). The outcome hinges heavily on assumptions, so read the point estimate with caution. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Xlife Sciences AG

How large is the market capitalisation of Xlife Sciences AG (XLS)?
The market capitalisation of Xlife Sciences AG is CHF 102M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Xlife Sciences AG (XLS)?
Earnings per share at Xlife Sciences AG are CHF −3.76. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Xlife Sciences AG (XLS)?
The return on equity (ROE) of Xlife Sciences AG is −7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xlife Sciences AG (XLS)?
On an EBIT basis the return on assets of Xlife Sciences AG is −3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xlife Sciences AG (XLS)?
The operating margin of Xlife Sciences AG is 28,004% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xlife Sciences AG (XLS)?
Revenue at Xlife Sciences AG is growing +1.3% versus a year earlier (3y avg −35.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Xlife Sciences AG (XLS)?
Earnings per share at Xlife Sciences AG are growing +94.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Xlife Sciences AG (XLS) generate?
The free cash flow of Xlife Sciences AG is −CHF 1.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Xlife Sciences AG (XLS) carry?
The net debt of Xlife Sciences AG is CHF 59.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Xlife Sciences AG in the live analysis

One click puts Xlife Sciences AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.